Ou · 2024 · Journal of autism and developmental disorders
A multicenter trial of 108 participants and results by rater
Did caregiver and clinician ratings agree in the same trial?
Human · multicenter randomized double-blind controlled trial
Key findings
Results differed by rater.
In a multicenter trial of 108 participants, clinician ratings improved, and about one-third of participants had score reductions of at least 30%. Caregiver ratings showed no significant difference between groups.
Results Differed by Rater
108-person multicenter controlled trial · 12 weeks
- Caregiver rating
- Not significant
- Clinician rating
- Signal of improvement
Results varied by rater and scale within the same trial.
Caregiver and clinician ratings were analyzed separately.
Read the original paper and sources ↓Detailed results
Results also differed by rater in the multicenter trial of 108 participants.
A 12-week randomized double-blind trial in China assessed more children across multiple centers than earlier small studies. Caregiver scales showed no significant difference between sulforaphane and placebo, while clinician scales reported improvement in the sulforaphane group.
| Assessment | Reported results |
|---|---|
| Caregiver-completed scales | No significant difference versus placebo |
| Clinician-rated scale | Significant improvement in the sulforaphane group |
| Exploratory analysis by age | A larger effect was reported in participants older than 10 years. |
Source: paper abstract.
What does a “30% reduction” mean?
The authors reported that approximately one-third of participants had assessment scores at least 30% lower at 12 weeks. Improvement was seen in clinician ratings; caregiver ratings were not significant.
What additional analyses show
The authors reported effects across several intelligence levels, with a larger effect in participants older than 10 years. They also proposed differences between raters for follow-up research. Yang's study is a subsequent microbiome analysis of some participants in this trial.
Study design
Tablets and placebo were compared for 12 weeks across several centers. Caregivers and clinicians separately rated children's behavior and social responsiveness.
- Participants
- 108 children with ASD in China
Multicenter randomized double-blind trial - Intake and observation
- Tablets containing GLR and active myrosinase
Weight-based dose · 12 weeks - Measures
- Caregiver-rated and clinician-rated scales
Study context
Published online in 2022 and assigned to a 2024 volume and issue. Yang's gut microbiome study is a follow-up analysis of some participants in this trial.
Original paper and sources
Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial.
- Journal
- Journal of autism and developmental disorders · 2024 · 54(2): 628-641
- First published
- 2022-11-24